# How cells spend and rebuild NAD+

> Arizona IV Therapy: inside the NAD+ pool — Arizona IV Therapy follows extracellular NAD in cultured cells, the mouse CD38 findings and the biology that makes replenishment more complicated.

**Cell biology**

The refill metaphor becomes more interesting when the contents are constantly being used, remade and handled differently across the cell boundary.

## A busy pool

The word “pool” invites a still-water picture. The [review of NAD+ in metabolism describes electron transfer and its use as a substrate by signalling enzymes](https://pubmed.ncbi.nlm.nih.gov/26785480/); those are active jobs. Another [review of NAD+ homeostasis describes depletion arising from impaired synthesis, increased consumption or dietary deficiency of vitamin B3 precursors](https://pubmed.ncbi.nlm.nih.gov/34041853/).

For me, that is where replenishment becomes a worthwhile idea. A low level can have a cause, and a cause can matter to an intervention. I suspect questions about production and consumption will prove more revealing than an assumption that adding more resolves every possible shortage.

The review gives a biological rationale for investigating replenishment. It does not assign a cause of tiredness to any reader or identify a personal deficiency. A diagnosis would require information this notebook cannot supply.

## The fibroblast dish

The [experiment in cultured human skin fibroblasts followed the metabolic fate of extracellular NAD](https://pubmed.ncbi.nlm.nih.gov/11135366/). Surface enzymes degraded it into nicotinamide, nicotinamide mononucleotide and purine metabolites. Adenosine was the principal hydrolysis product taken up by the cells and was further metabolised into intracellular ATP.

That sequence gets me closer to an explanation than a simple claim of cellular delivery. The experiment names the things on either side of the boundary. “Extracellular” just means outside the cell; the location is doing important work in that sentence.

These were cultured human cells. I regard the observation as a challenge to an overly tidy illustration of replenishment. Measuring a person's response to an infusion would be a separate task, with tissues and outcomes of its own.

![Two technicians examine a cell-culture dish beside a bench microscope.](images/cell-culture-bench.webp)

*An imagined laboratory scene, illustrating the scale of cell-culture work rather than the laboratory or people in the paper.*

## CD38 and the ageing mice

In [the mouse study of CD38 and age-related NAD decline, deletion of CD38 protected against the decline in tissue NAD+](https://pubmed.ncbi.nlm.nih.gov/27304511/). CD38 is an enzyme that consumes NAD+. The paper reports preserved NAD+ levels and SIRT3 activity, with better mitochondrial function and metabolic health as the mice aged.

I admire how this experiment changes the replenishment question. It examines what consumes the pool. Genetic deletion in mice gives that question an unusually sharp test, although it remains far removed from supplying NAD+ to a person.

The same result also makes the container metaphor feel inadequate. Here an alteration to an enzyme changes the pool and its associated biology. The study's intervention was a genetic change in mice; it offers no human dosing instruction.

## Tissue measurements

The [review of human NAD+ precursor trials in ageing calls tissue-specific NAD+ data sparse](https://pubmed.ncbi.nlm.nih.gov/41083806/). It also describes limited clinical efficacy and says consistent observation of age-related NAD+ decline comes from a limited number of human studies.

At first, I expected the replenishment argument to turn mainly on supply. The more compelling problem is connecting supply, the tissue of interest and a useful outcome. That connection makes a claim testable in a way that “topping up” leaves vague.

The [oral NMN trials](/oral-trials) move into that problem with blood NAD+, muscle insulin sensitivity and walking distance. Those are different measurements, and the differences make the trials worth reading.

---

Here I follow the NAD+ replenishment story through published research; Arizona IV Therapy offers an editorial notebook, no treatment business and no medical advice.